-->

Company Registry

Nano Biotherapeutics Inc
Profile last edited on: 7/10/2020

Drug platform to treate acute and chronic tissue inflammation and tissue injury in the heart and lungs.
Year Founded
2016
First SBIR Year
2015
Latest SBIR Award
2019
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2201 West Campbell Park Drive Suite 326
Chicago, IL 60612
   (877) 331-6168
   info@nanobiotherapeutics.com
   nanobiotherapeutics.com
Multiple Locations:   
Congressional District:   07
County:   Cook

Public Profile

Nano Biotherapeutics Inc is developing a drug platform to treat acute and chronic inflammation and tissue injury in the heart and lungs using albumin nanoparticle mediated drug delivery. The nano drug platform is based on albumin, a natural protein, and the firm's nanoparticle can entrap small hydophobic drugs.The nanoparticel is loaded with an anti-inflammatory drug to target activated neutrophils, which accumulates at the site of injury. Then, the released drug suppresses inflammation.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2019 2 NIH $3,387,167
HLS13-13 Albumin Nanoparticle Based Technology to Treat Ards

Key People / Management

  Asrar B Malik -- CEO

  Prasad V S Kantet --

  Andrew Stuart -- Senior Scientist

SBIR firms in the news

There are no news available.